MannKind (MNKD) announced that the first patient has been enrolled in INHALE-1ST, a clinical study evaluating the initiation of Afrezza Inhalation Powder shortly after a type 1 diabetes diagnosis in pediatric patients.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNKD:
- Morning Movers: USA Rare Earth surges after government funding pact
- MannKind receives FDA approval for Afrezza dosage label
- MannKind Targets Newly Diagnosed Youth With Afrezza: What Investors Should Watch
- Multiple 2026 Regulatory, Pipeline, and Partnership Catalysts Underscore MannKind’s Underappreciated Growth Potential and Support Reiterated Buy Rating
- MannKind shares not pricing in ‘multiple tailwinds,’ says H.C. Wainwright